Armata Pharmaceuticals, Inc.
AMEX:ARMPBiotechnology
Healthcare
$2.98 -0.28%
-$0.02 today
- Market cap
- $110.83M
- Beta
- 1.22
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$7.74
52W Low $1.81High $16.34
Volume 0.07M
Average 0.07M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$25.76M
FY 2025 · Annual
Investing Cash Flow
-$542,000.00
FY 2025 · Annual
Financing Cash Flow
$25.61M
FY 2025 · Annual
-26.7% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (23.16M) | (36.92M) | (69.05M) | (18.92M) | (173.8M) |
| Depreciation & Amortization | 1.17M | 892K | 972K | 1.33M | 1.53M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.88M | 3.11M | 938K | 2.89M | 2.61M |
| Change in Working Capital | (3.22M) | 439K | (9.65M) | (2.1M) | (1.41M) |
| Accounts Receivables | (2.43M) | 1.05M | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 184K | 3.67M | 39K | (3.76M) | (334K) |
| Other Working Capital | (979K) | (4.28M) | (9.69M) | 1.66M | (1.08M) |
| Other Non-Cash Items | (1.25M) | 0 | 29.36M | (20.75M) | 145.31M |
| Operating Cash Flow | (23.58M) | (32.48M) | (47.42M) | (37.55M) | (25.76M) |
| Capital Expenditures | (1.3M) | (2.21M) | (8.14M) | (1.88M) | (542K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 10K | 0 | 0 |
| Investing Cash Flow | (1.3M) | (2.21M) | (8.13M) | (1.88M) | (542K) |
| Debt Repayment | 0 | 0 | 54.03M | 34.89M | 25M |
| Common Stock Issued | 26.32M | 44.52M | 5K | 130K | 658K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (801K) | (500K) | (43K) | (61K) | (46K) |
| Financing Cash Flow | 25.52M | 44.02M | 53.99M | 34.96M | 25.61M |
| Effect of Forex Changes | 0 | (4.76M) | 0 | 0 | 0 |
| Net Change in Cash | 639K | 4.56M | (1.57M) | (4.47M) | (693K) |
| Free Cash Flow | (24.88M) | (34.69M) | (55.57M) | (39.43M) | (26.31M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$173.8M
+ D&A$1.5M
+ Stock-Based Comp$2.6M
+ Deferred Tax$0
- Working Capital-$1.4M
+ Other Non-Cash$145.3M
= Operating Cash Flow-$25.8M
- Capex-$542.0K
= Free Cash Flow-$26.3M
Analysis
FY2025 free cash flow is -$26.3M. FCF conversion is 15.1% of net income. Operating cash flow was -$25.8M, with capex of -$542.0K. The largest bridge item is Other Non-Cash at $145.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Sep 23, 2026 | |
| 8-K | Current report | Sep 14, 2026 | |
| 10-Q | Quarterly report | Aug 12, 2026 |
Does ARMP generate free cash flow?
Armata Pharmaceuticals, Inc. (ARMP) generated -$26.30M of free cash flow in fiscal 2025.
How much operating cash flow does ARMP produce?
Operating cash flow was -$25.76M, before capital expenditures of $542,000.00.
Continue the stock analysis
Jump to another research area for this company.